HUTCHMED (China) (HKG:0013) said a phase 3 clinical trial of sovleplenib to treat an autoimmune disorder met its primary goal, according to a Hong Kong bourse filing Wednesday.
The drug was found to induce durable hemoglobin response rate between five to 24 weeks of treatment in adult patients with warm antibody autoimmune hemolytic anemia in China, the firm said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments